- Home
- MDXH vs CNTB Comparison
MDXH vs CNTB Comparison
Compare MDXH & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDXH | CNTB |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.0M | 128.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MDXH | CNTB |
|---|---|---|
| Price | $2.30 | $2.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.67 | ★ $8.50 |
| AVG Volume (30 Days) | 156.6K | ★ 239.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,033,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.31 | $17,706.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $0.51 |
| 52 Week High | $5.33 | $3.82 |
Technical Indicators
Market Signals| Indicator | MDXH | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 18.64 | 45.46 |
| Support Level | $1.90 | $2.16 |
| Resistance Level | $2.30 | $2.78 |
| Average True Range (ATR) | 0.20 | 0.35 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 3.45 | 7.87 |
Price Performance
Historical ComparisonAbout MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.